SCM
PCSA icon

Stonepine Capital Management’s Processa Pharmaceuticals PCSA Stock Holding History

Stonepine Capital Management’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Buy
55,000
+42,677
+346% +$117K 0.06% 76
2025
Q4 		$35.5K Sell
12,323
-28,885
-70% -$202K 0.03% 66
2025
Q3 		$198K Buy
+41,208
New +$218K 0.16% 54

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Stonepine Capital Management's PCSA Position: Q1 2026 in Review

Stonepine Capital Management increased its Processa Pharmaceuticals (PCSA) stake by 346% in Q1 2026, buying an estimated $117K and bringing the position to 55,000 shares worth $139K. The position accounts for 0.06% of the portfolio, ranked #76.

Stonepine Capital Management first reported a position in PCSA in Q3 2025 and has held it in 3 quarters since. The position peaked at $198K in Q3 2025. 10 funds tracked by Wall St. Rank hold PCSA as of Q1 2026.

  • Stonepine Capital Management held 55,000 shares of Processa Pharmaceuticals worth $139K as of Q1 2026.
  • Stonepine Capital Management bought 42,677 Processa Pharmaceuticals shares in Q1 2026, an estimated $117K.
  • Processa Pharmaceuticals made up 0.06% of Stonepine Capital Management's portfolio in Q1 2026, its #76 holding.
  • Stonepine Capital Management first reported a position in Processa Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Stonepine Capital Management's Processa Pharmaceuticals position peaked at $198K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.